PE20210176A1 - Inhibidores de arginasa y sus metodos de uso - Google Patents
Inhibidores de arginasa y sus metodos de usoInfo
- Publication number
- PE20210176A1 PE20210176A1 PE2020001241A PE2020001241A PE20210176A1 PE 20210176 A1 PE20210176 A1 PE 20210176A1 PE 2020001241 A PE2020001241 A PE 2020001241A PE 2020001241 A PE2020001241 A PE 2020001241A PE 20210176 A1 PE20210176 A1 PE 20210176A1
- Authority
- PE
- Peru
- Prior art keywords
- methods
- boronobutyl
- compounds
- carboxylic acid
- formula
- Prior art date
Links
- 102000004452 Arginase Human genes 0.000 title abstract 2
- 108700024123 Arginases Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- SHQWTXRBVVLSOY-VXNVDRBHSA-N (2R,4R)-4-amino-2-(4-boronobutyl)pyrrolidine-2-carboxylic acid Chemical compound C(CCB(O)O)C[C@]1(NC[C@H](N)C1)C(=O)O SHQWTXRBVVLSOY-VXNVDRBHSA-N 0.000 abstract 1
- VVDSEBYTWQOURR-IONNQARKSA-N (2R,4S)-2-(4-boronobutyl)-4-hydroxypyrrolidine-2-carboxylic acid Chemical compound B(O)(O)CCCC[C@]1(NC[C@H](C1)O)C(=O)O VVDSEBYTWQOURR-IONNQARKSA-N 0.000 abstract 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se divulga compuestos de formula (I); donde R1 es -NHR1a; R1a es -H o -C(O)CH(R1b)NHR1c; R1b se selecciona entre -H, -alquilo(C1-C4) y CH2OR1d; R1c es -H; o R1b y R1c, junto con el atomo al que estan unidos, forman un anillo heterociclico de 5 miembros; y R1d es H o -CH3; y una sal farmaceuticamente aceptable de estos. Un compuesto seleccionado es acido (2R,4S)-2-(4-boronobutil)-4-hidroxipirrolidin-2-carboxilico; acido (2R,4R)-4-amino-2-(4-boronobutil)pirrolidin-2-carboxilico. Dichos compuestos son inhibidores de la actividad de la arginasa. Tambien refiere a una composicion farmaceutica que comprende al compuesto formula (I) y metodos para utilizarlas en el tratamiento del cancer o una enfermedad respiratoria inflamatoria.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862631659P | 2018-02-17 | 2018-02-17 | |
| US201862671576P | 2018-05-15 | 2018-05-15 | |
| US201862721113P | 2018-08-22 | 2018-08-22 | |
| US201862778002P | 2018-12-11 | 2018-12-11 | |
| PCT/IB2019/051236 WO2019159120A1 (en) | 2018-02-17 | 2019-02-15 | Arginase inhibitors and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20210176A1 true PE20210176A1 (es) | 2021-01-29 |
Family
ID=65763693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020001241A PE20210176A1 (es) | 2018-02-17 | 2019-02-15 | Inhibidores de arginasa y sus metodos de uso |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US11420984B2 (es) |
| EP (1) | EP3752251A1 (es) |
| JP (2) | JP7317841B2 (es) |
| KR (1) | KR102657919B1 (es) |
| CN (3) | CN117180290A (es) |
| AU (2) | AU2019221896B2 (es) |
| BR (1) | BR112020015973A2 (es) |
| CA (1) | CA3091365A1 (es) |
| CL (1) | CL2020002096A1 (es) |
| CR (1) | CR20200418A (es) |
| DO (1) | DOP2020000145A (es) |
| EC (1) | ECSP20058183A (es) |
| IL (1) | IL276711B2 (es) |
| JO (1) | JOP20200197A1 (es) |
| MA (1) | MA51837A (es) |
| MX (1) | MX2020008570A (es) |
| NI (1) | NI202000055A (es) |
| PE (1) | PE20210176A1 (es) |
| SG (1) | SG11202007739XA (es) |
| TW (1) | TWI803574B (es) |
| UY (1) | UY38096A (es) |
| WO (1) | WO2019159120A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI803574B (zh) * | 2018-02-17 | 2023-06-01 | 瑞典商阿斯特捷利康公司 | 精胺酸酶抑制劑及其使用方法 |
| US20190292188A1 (en) | 2018-02-27 | 2019-09-26 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors |
| WO2019186497A1 (en) | 2018-03-29 | 2019-10-03 | Oncoarendi Therapeutics S.A. | Dipeptide piperidine derivatives |
| CA3100731A1 (en) | 2018-05-18 | 2019-11-21 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| CA3105721A1 (en) | 2018-07-05 | 2020-01-09 | Incyte Corporation | Fused pyrazine derivatives as a2a / a2b inhibitors |
| KR102668252B1 (ko) | 2018-08-22 | 2024-05-21 | 아스트라제네카 아베 | 아르기나제 저해제 및 이의 사용 방법 |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| SI3921033T1 (sl) * | 2019-02-08 | 2023-11-30 | Astrazeneca Ab | Zaviralci arginaze in postopki njihove uporabe |
| EP4054591A1 (en) * | 2019-11-04 | 2022-09-14 | Astrazeneca AB | Combination therapy for treating cancer |
| TW202228720A (zh) * | 2020-12-22 | 2022-08-01 | 波蘭商昂科艾倫迪治療法股份公司 | 精胺酸酶抑制劑及其使用方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104876955B (zh) * | 2010-04-22 | 2018-11-23 | 马尔斯公司 | 精氨酸酶抑制剂及其治疗应用 |
| ES2568680T3 (es) | 2010-10-26 | 2016-05-03 | Mars, Incorporated | Boratos como inhibidores de arginasa |
| CN104857005B (zh) * | 2010-12-31 | 2019-04-26 | 阿斯利康公司 | 精氨酸酶抑制剂及其使用方法 |
| WO2013158262A1 (en) | 2012-04-18 | 2013-10-24 | Mars, Incorporated | Ring constrained analogs as arginase inhibitors |
| US10143699B2 (en) * | 2015-06-23 | 2018-12-04 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
| UA125289C2 (uk) | 2015-10-30 | 2022-02-16 | Калітера Байосайєнсиз, Інк. | Композиції і способи для інгібування активності аргінази |
| PL417066A1 (pl) | 2016-05-04 | 2017-11-06 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
| WO2018089490A1 (en) * | 2016-11-08 | 2018-05-17 | Calithera Biosciences, Inc. | Arginase inhibitor combination therapies |
| LT3559009T (lt) | 2016-12-22 | 2021-06-25 | Calithera Biosciences, Inc. | Kompozicijos ir būdai, skirti arginazės aktyvumo slopinimui |
| CN111491937A (zh) | 2017-12-22 | 2020-08-04 | 广东新契生物医药科技有限公司 | 作为精氨酸酶抑制剂的杂环化合物 |
| TWI803574B (zh) * | 2018-02-17 | 2023-06-01 | 瑞典商阿斯特捷利康公司 | 精胺酸酶抑制劑及其使用方法 |
| WO2019177873A1 (en) | 2018-03-13 | 2019-09-19 | Merck Sharp & Dohme Corp. | Arginase inhibitors and methods of use |
| WO2019205979A1 (zh) | 2018-04-27 | 2019-10-31 | 四川科伦博泰生物医药股份有限公司 | 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途 |
| WO2019218904A1 (zh) | 2018-05-18 | 2019-11-21 | 四川科伦博泰生物医药股份有限公司 | 非天然氨基酸类衍生物、其制备方法及用途 |
| US11274111B2 (en) | 2018-06-20 | 2022-03-15 | Merck Sharp & Dohme Corp. | Arginase inhibitors and methods of use |
-
2019
- 2019-02-15 TW TW108105043A patent/TWI803574B/zh active
- 2019-02-15 BR BR112020015973-5A patent/BR112020015973A2/pt unknown
- 2019-02-15 CN CN202311157009.9A patent/CN117180290A/zh active Pending
- 2019-02-15 JO JOP/2020/0197A patent/JOP20200197A1/ar unknown
- 2019-02-15 PE PE2020001241A patent/PE20210176A1/es unknown
- 2019-02-15 IL IL276711A patent/IL276711B2/en unknown
- 2019-02-15 CR CR20200418A patent/CR20200418A/es unknown
- 2019-02-15 MA MA051837A patent/MA51837A/fr unknown
- 2019-02-15 WO PCT/IB2019/051236 patent/WO2019159120A1/en active Application Filing
- 2019-02-15 CN CN202311155200.XA patent/CN117186134A/zh active Pending
- 2019-02-15 MX MX2020008570A patent/MX2020008570A/es unknown
- 2019-02-15 CN CN201980013045.3A patent/CN111712302B/zh active Active
- 2019-02-15 KR KR1020207026580A patent/KR102657919B1/ko active IP Right Grant
- 2019-02-15 AU AU2019221896A patent/AU2019221896B2/en active Active
- 2019-02-15 CA CA3091365A patent/CA3091365A1/en active Pending
- 2019-02-15 US US16/969,739 patent/US11420984B2/en active Active
- 2019-02-15 JP JP2020543307A patent/JP7317841B2/ja active Active
- 2019-02-15 UY UY0001038096A patent/UY38096A/es unknown
- 2019-02-15 SG SG11202007739XA patent/SG11202007739XA/en unknown
- 2019-02-15 EP EP19710796.4A patent/EP3752251A1/en active Pending
-
2020
- 2020-07-22 DO DO2020000145A patent/DOP2020000145A/es unknown
- 2020-08-13 CL CL2020002096A patent/CL2020002096A1/es unknown
- 2020-08-14 NI NI202000055A patent/NI202000055A/es unknown
- 2020-09-16 EC ECSENADI202058183A patent/ECSP20058183A/es unknown
-
2022
- 2022-06-07 AU AU2022203938A patent/AU2022203938B2/en active Active
- 2022-07-15 US US17/812,736 patent/US20230122859A1/en active Pending
-
2023
- 2023-07-10 US US18/349,336 patent/US11912727B2/en active Active
- 2023-07-19 JP JP2023117406A patent/JP2023145557A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20210176A1 (es) | Inhibidores de arginasa y sus metodos de uso | |
| CO2021015698A2 (es) | Moduladores de thr-β y métodos de uso de estos | |
| PE20230238A1 (es) | Inhibidores de kras g12c | |
| EA201891191A1 (ru) | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения | |
| PE20091556A1 (es) | Derivado heterociclico fusionado y su uso | |
| UY29869A1 (es) | Compuestos de benzamida | |
| EA202092975A1 (ru) | Селективные супрессоры рецептора эстрогена | |
| PE20070179A1 (es) | Derivados de purina como agonistas del receptor de adenosina a2 | |
| CO2021010493A2 (es) | Compuestos de halo-alilamina y uso de los mismos | |
| PH12021550374A1 (en) | Small molecule menin inhibitors | |
| UY38964A (es) | Derivados de 1,2,4-oxadiazol como agonistas del receptor hepático x, sus usos y métodos relacionados referencia cruzada a solicitudes relacionadas | |
| AR119857A1 (es) | Compuestos de pirazol, formulaciones de los mismos y su uso para la inhibición de una proteína irak | |
| ECSP22027784A (es) | Derivados de 2azaespiro[3.4]octano como agonistas de m4 | |
| CL2022000893A1 (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 | |
| CO2021011039A2 (es) | Inhibidores de arginasa y métodos de uso de estos | |
| PE20181450A1 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer | |
| ECSP22054240A (es) | Compuesto y composici?n como inhibidor de quinasa del receptor pdgf | |
| ATE525360T1 (de) | Neuartige imidazolinylmethyl-aryl-sulfonamide | |
| EA202091886A1 (ru) | Ингибиторы аргиназы и способы их применения | |
| EA202090241A1 (ru) | Новые гетероциклические соединения как ингибиторы cdk8/19 | |
| AR120156A1 (es) | Compuestos quiméricos de somatostatina-dopamina estables de almacenamiento y las formas salinas de estos | |
| AR114394A1 (es) | Inhibidores de arginasa y sus métodos de uso | |
| EA202092345A1 (ru) | Пиперидиновые соединения в качестве ковалентных ингибиторов менина | |
| EA202090982A1 (ru) | Производные бензимидазола и варианты их применения |